# KLOW Peptide Dosage in the Research Literature | KLOW Order

> KLOW peptide dosage data from the preclinical literature: per-component studied doses for BPC-157, TB-500, GHK-Cu, and KPV, plus route, half-life, storage, and reconstitution research context.

## Per-Component Doses Studied in Preclinical Literature

KLOW peptide dosage data from the published literature is component-specific. No study establishes a validated dosage for the four-peptide combination.

**BPC-157:** Most rodent studies use 10 μg/kg/day administered intraperitoneally [4][23]. Ultra-low-dose efficacy has been demonstrated at 10 ng/kg. Pharmacokinetic studies used 20, 100, and 500 μg/kg (IM) in rats and dogs [6].

**TB-500 / thymosin beta-4:** Wound healing models have used 0.5-10 mg/kg in topical and intraperitoneal administration. The key finding: 42% and 61% reepithelialization improvement at days 4 and 7 [8].

**GHK-Cu:** In fibroblast cell culture, collagen synthesis stimulation begins at 10^-12 M and maximizes at 10^-9 M [10]. Wound dressing studies have used 10 μg/mL with a 9-fold collagen production increase in healthy rats [12].

**KPV:** NF-kB suppression at ≥1 μg/mL in bronchial epithelial cell cultures [15]. Murine colitis models use nanomolar oral concentrations via PepT1 transport [16].

## KLOW Peptide Protocol: Research Framing and Cycle Structure

BPC-157 rodent injury studies range from 7-day acute tendon transection models [4] to 90-day ligament healing studies [23]. No published study establishes a consensus cycle length for the four-peptide KLOW combination.

## Half-Life and Pharmacokinetics in the KLOW Research Context

BPC-157 pharmacokinetics: IV elimination half-life 15.2 minutes in rats and 5.27 minutes in dogs; IM Tmax approximately 3 minutes; absolute bioavailability 14-19% in rats and 45-51% in dogs; linear pharmacokinetics at all studied doses [6].

TB-500: No published pharmacokinetic data for the Ac-LKKTETQ synthetic fragment.

GHK-Cu: Endogenous plasma concentrations ~200 ng/mL at age 20, declining to ~80 ng/mL by age 60 [26].

KPV: PepT1 transporter kinetics drive intestinal uptake; PepT1 expression is upregulated in the inflamed colon [16][17].

## KLOW Peptide Storage and Stability

Lyophilized peptide blends are typically stored at -20°C long-term and 2-8°C after reconstitution. GHK-Cu upon reconstitution imparts a characteristic blue-green color due to copper(II) chelation [24] — this is expected and normal.

## Injection Site Research in Peptide Studies

For BPC-157 rodent studies, intraperitoneal injection is the most common route [4][23]. BPC-157 has also been administered orally in rodent colitis models with demonstrated mucosal healing effects [5]. GHK-Cu is administered topically in most skin and wound studies. KPV is administered orally in colitis models (exploiting PepT1 uptake) [14][16].

## Reconstituting KLOW: What Research Protocols Use

Research-grade lyophilized peptide vials are reconstituted with bacteriostatic water for injection. A common laboratory ratio for an 80 mg vial is 2 mL. The reconstituted KLOW solution will be blue-green due to GHK-Cu's copper chelation [24].

## References

[4] Krivic A et al. BPC 157: tendon-to-bone healing. J Orthop Res. 2006;24(5):982-989. https://pubmed.ncbi.nlm.nih.gov/16583442/
[5] Sikiric P et al. BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632. https://pubmed.ncbi.nlm.nih.gov/21548867/
[6] He L et al. Pharmacokinetics of BPC-157. Front Pharmacol. 2022;13:1026182. https://pmc.ncbi.nlm.nih.gov/articles/PMC9794587/
[8] Malinda KM et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. https://pubmed.ncbi.nlm.nih.gov/10469335/
[10] Maquart FX et al. Stimulation of collagen synthesis by GHK-Cu2+. FEBS Lett. 1988;238(2):343-346. https://pubmed.ncbi.nlm.nih.gov/3169264/
[11] Pickart L et al. GHK Peptide in Skin Regeneration. Biomed Res Int. 2015;2015:648108. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
[12] Pickart L, Margolina A. Regenerative Actions of GHK-Cu. Int J Mol Sci. 2018;19(7):1987. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
[13] Wang X et al. GHK-Cu-liposomes accelerate scald wound healing. Wound Repair Regen. 2017;25(2):270-278. https://pubmed.ncbi.nlm.nih.gov/28370978/
[14] Kannengiesser K et al. KPV anti-inflammatory potential in murine IBD models. Inflamm Bowel Dis. 2008;14(3):324-331. https://pubmed.ncbi.nlm.nih.gov/18092346/
[15] Land SC. Mechanism of KPV action. Int J Physiol Pathophysiol Pharmacol. 2012;4(2):59-73. https://pmc.ncbi.nlm.nih.gov/articles/PMC3403564/
[16] Dalmasso G et al. PepT1-mediated KPV uptake. Gastroenterology. 2008;134(1):166-178. https://pubmed.ncbi.nlm.nih.gov/18061177/
[17] Viennois E et al. PepT1 in colitis-associated cancer. Cell Mol Gastroenterol Hepatol. 2016;2(3):340-357. https://pubmed.ncbi.nlm.nih.gov/27458604/
[23] Cerovecki T et al. BPC 157 improves ligament healing. J Orthop Res. 2010;28(9):1155-1161. https://pubmed.ncbi.nlm.nih.gov/20225319/
[24] Pickart L, Margolina A. [GHK-Cu copper chelation reference] Int J Mol Sci. 2018;19(7):1987. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
[26] Pickart L et al. GHK-Cu in prevention of oxidative stress and aging. Oxid Med Cell Longev. 2012;2012:324832. https://pubmed.ncbi.nlm.nih.gov/22666519/
[29] Yuan C et al. BPC-157 in Tissue Repair and Pain Management. Int J Mol Sci. 2026;27(6):2876. https://pubmed.ncbi.nlm.nih.gov/41898733/

---

Four spot-ink literatures, one dark-stock page — editorial summaries of what the peer-reviewed studies actually printed, held by no clinic and sold by no one.